Value through Innovation27 July 2016

What is a lay summary?

To view this video in other translations click on the language below:
Chinese (simplified)
Chinese (traditional)
Portuguese (Brazilian)

Clinical Study Results

  • AGGRENOX ® - Coronary Artery Disease
    Clinical Study Number 9.169
    Study Indication Coronary Artery Disease
    Product AGGRENOX ®
    Generic Name Dipyridamole + Acetylsalicylic acid
    Lab Code
    Clinical Phase IV
    Study Title

    A randomised, crossover study comparing the biochemical and platelet effects of modified-release dipyridamole/aspirin (200mg/25 mg bd; Asasantin Retard®) with aspirin (75 mg qd) in coronary artery disease patients with aspirin resistance manifesting as persistent thromboxane formation.

    Study Document
    Trial synopsis 9.169_CO english
  • BI 695500 - Coronary Artery Disease , Lymphoma, Non-Hodgkin
    Clinical Study Number 1301.2
    Study Indication Coronary Artery Disease ; Lymphoma, Non-Hodgkin
    Product BI 695500
    Generic Name BI 695500
    Lab Code BI 695500
    Clinical Phase III
    Study Title

    A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non- Hodgkin’s lymphoma

    Study Document
    Trial statement 1301.2 english